Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines - PubMed (original) (raw)

. 1999 Oct 1;274(40):28395-404.

doi: 10.1074/jbc.274.40.28395.

Affiliations

• PMID: 10497200
• DOI: 10.1074/jbc.274.40.28395

Free article

Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines

G K Marathe et al. J Biol Chem. 1999.

Free article

Abstract

Oxidation of human low density lipoprotein (LDL) generates proinflammatory mediators and underlies early events in atherogenesis. We identified mediators in oxidized LDL that induced an inflammatory reaction in vivo, and activated polymorphonuclear leukocytes and cells ectopically expressing human platelet-activating factor (PAF) receptors. Oxidation of a synthetic phosphatidylcholine showed that an sn-1 ether bond confers an 800-fold increase in potency. This suggests that rare ether-linked phospholipids in LDL are the likely source of PAF-like activity in oxidized LDL. Accordingly, treatment of oxidized LDL with phospholipase A(1) greatly reduced phospholipid mass, but did not decrease its PAF-like activity. Tandem mass spectrometry identified traces of PAF, and more abundant levels of 1-O-hexadecyl-2-(butanoyl or butenoyl)-sn-glycero-3-phosphocholines (C(4)-PAF analogs) in oxidized LDL that comigrated with PAF-like activity. Synthesis showed that either C(4)-PAF was just 10-fold less potent than PAF as a PAF receptor ligand and agonist. Quantitation by gas chromatography-mass spectrometry of pentafluorobenzoyl derivatives shows the C(4)-PAF analogs were 100-fold more abundant in oxidized LDL than PAF. Oxidation of synthetic alkyl arachidonoyl phosphatidylcholine generated these C(4)-PAFs in abundance. These results show that quite minor constituents of the LDL phosphatidylcholine pool are the exclusive precursors for PAF-like bioactivity in oxidized LDL.

PubMed Disclaimer

Similar articles

• Identification of platelet-activating factor as the inflammatory lipid mediator in CCl4-metabolizing rat liver.
  Marathe GK, Harrison KA, Roberts LJ 2nd, Morrow JD, Murphy RC, Tjoelker LW, Prescott SM, Zimmerman GA, McIntyre TM. Marathe GK, et al. J Lipid Res. 2001 Apr;42(4):587-96. J Lipid Res. 2001. PMID: 11290831
• Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation.
  Androulakis N, Durand H, Ninio E, Tsoukatos DC. Androulakis N, et al. J Lipid Res. 2005 Sep;46(9):1923-32. doi: 10.1194/jlr.M500074-JLR200. Epub 2005 Jul 1. J Lipid Res. 2005. PMID: 15995176
• Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group.
  Tanaka T, Iimori M, Tsukatani H, Tokumura A. Tanaka T, et al. Biochim Biophys Acta. 1994 Jan 3;1210(2):202-8. doi: 10.1016/0005-2760(94)90122-8. Biochim Biophys Acta. 1994. PMID: 8280771
• Oxidized LDL contains inflammatory PAF-like phospholipids.
  Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM. Marathe GK, et al. Trends Cardiovasc Med. 2001 Apr-May;11(3-4):139-42. doi: 10.1016/s1050-1738(01)00100-1. Trends Cardiovasc Med. 2001. PMID: 11686003 Review.
• Bioactive phospholipid oxidation products.
  Marathe GK, Harrison KA, Murphy RC, Prescott SM, Zimmerman GA, McIntyre TM. Marathe GK, et al. Free Radic Biol Med. 2000 Jun 15;28(12):1762-70. doi: 10.1016/s0891-5849(00)00234-3. Free Radic Biol Med. 2000. PMID: 10946218 Review.

Cited by

• Whole-Genome Resequencing of Xiangxi Cattle Identifies Genomic Diversity and Selection Signatures.
  Luo X, Li J, Xiao C, Sun L, Xiang W, Chen N, Lei C, Lei H, Long Y, Long T, Suolang Q, Yi K. Luo X, et al. Front Genet. 2022 May 27;13:816379. doi: 10.3389/fgene.2022.816379. eCollection 2022. Front Genet. 2022. PMID: 35711927 Free PMC article.
• Redox (phospho)lipidomics of signaling in inflammation and programmed cell death.
  Tyurina YY, St Croix CM, Watkins SC, Watson AM, Epperly MW, Anthonymuthu TS, Kisin ER, Vlasova II, Krysko O, Krysko DV, Kapralov AA, Dar HH, Tyurin VA, Amoscato AA, Popova EN, Bolevich SB, Timashev PS, Kellum JA, Wenzel SE, Mallampalli RK, Greenberger JS, Bayir H, Shvedova AA, Kagan VE. Tyurina YY, et al. J Leukoc Biol. 2019 Jul;106(1):57-81. doi: 10.1002/JLB.3MIR0119-004RR. Epub 2019 May 9. J Leukoc Biol. 2019. PMID: 31071242 Free PMC article. Review.
• Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF.
  Chaithra VH, Jacob SP, Lakshmikanth CL, Sumanth MS, Abhilasha KV, Chen CH, Thyagarajan A, Sahu RP, Travers JB, McIntyre TM, Kemparaju K, Marathe GK. Chaithra VH, et al. J Lipid Res. 2018 Nov;59(11):2063-2074. doi: 10.1194/jlr.M085704. Epub 2018 Aug 23. J Lipid Res. 2018. PMID: 30139761 Free PMC article.
• Platelet-activating factor receptor affects food intake and body weight.
  Li W, McIntyre TM. Li W, et al. Genes Dis. 2015 Sep;2(3):255-260. doi: 10.1016/j.gendis.2015.06.002. Epub 2015 Jun 24. Genes Dis. 2015. PMID: 29354667 Free PMC article.
• A Novel Mechanism for Atherosclerotic Calcification: Potential Resolution of the Oxidation Paradox.
  Riad A, Narasimhulu CA, Deme P, Parthasarathy S. Riad A, et al. Antioxid Redox Signal. 2018 Aug 10;29(5):471-483. doi: 10.1089/ars.2017.7362. Epub 2018 Jan 24. Antioxid Redox Signal. 2018. PMID: 29237273 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • Guide to Pharmacology